ctDNA-Based Detection of Residual Disease Prognostic for Resected CRC

MONDAY, Jan. 29, 2024 -- For patients with radically resected, stage II to IV colorectal cancer (CRC), circulating tumor (ct)DNA-based detection of molecular residual disease (MRD) in response to adjuvant chemotherapy (ACT) is prognostic of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news